Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Results 1 - 20 of 26 : 1 2 Next »

Recs

0
Member Avatar clangmead (29.32) Submitted: 4/20/2015 7:09:31 AM : Outperform Start Price: $28.17 DYAX Score: -3.83

eod

Recs

0
Member Avatar SamsaricSufferer (51.31) Submitted: 9/26/2013 8:42:15 PM : Underperform Start Price: $6.70 DYAX Score: -284.20

Technically very over bought.

Recs

1
Member Avatar gringo33339 (< 20) Submitted: 4/26/2013 5:32:29 PM : Outperform Start Price: $2.73 DYAX Score: +871.74

Buying opportunity today for this stock which will benefit greatly if LLY sees success in its Ramu pipeline drug candidate.

Recs

1
Member Avatar DEWBMW (< 20) Submitted: 5/24/2012 12:59:28 AM : Outperform Start Price: $1.69 DYAX Score: +1,464.09

Should break even on cash flow in 2013. Great time to get in. Only company I know that makes a drug for HAE.

Recs

1
Member Avatar stainsolution (78.08) Submitted: 4/9/2012 7:42:31 PM : Outperform Start Price: $1.57 DYAX Score: +1,594.35

Bio play

Recs

1
Member Avatar RBuskey106 (63.66) Submitted: 3/21/2012 11:29:57 AM : Outperform Start Price: $1.58 DYAX Score: +1,585.58

Chart looking good

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 3/11/2011 12:51:19 PM : Outperform Start Price: $1.57 DYAX Score: +1,585.79

Should get some play.

Recs

0
Member Avatar wofaintagain (< 20) Submitted: 10/15/2009 12:34:34 PM : Underperform Start Price: $3.22 DYAX Score: -658.20

until drug approval

Recs

0
Member Avatar biomedeng (67.90) Submitted: 12/31/2007 8:06:33 PM : Outperform Start Price: $3.87 DYAX Score: +559.41

The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their solutions (and the trials are quite promising), the drug will become very popular very quickly regardless of what the on-label indications are.

Recs

0
Member Avatar doggetla (65.50) Submitted: 10/26/2007 6:57:24 PM : Outperform Start Price: $4.50 DYAX Score: +465.72

great bio-tech partners - with lots of "magic beans" in pipeline

Recs

0
Member Avatar Dwaterman86 (< 20) Submitted: 10/4/2007 3:39:25 PM : Underperform Start Price: $3.82 DYAX Score: -574.43

better off investing in magic beans

Recs

0
Member Avatar hendrikvanlaar (< 20) Submitted: 9/11/2007 4:25:01 AM : Outperform Start Price: $3.98 DYAX Score: +537.10

finding a partner to sell their top drug will boost the stock (the successful completion of phase III sent the stock up by 50% in a day, but that didn't last. Make use of it)

Recs

0
Member Avatar fatcanibal (< 20) Submitted: 6/14/2007 4:17:27 PM : Outperform Start Price: $4.55 DYAX Score: +457.59

Well organized and focused

Recs

0
Member Avatar misterp946 (47.80) Submitted: 5/22/2007 3:41:43 PM : Outperform Start Price: $4.34 DYAX Score: +485.85

Hot New Products....stock took a beating....when Genzyme deal feel through...This stock due for a nice come back....sell on announcement

Recs

0
Member Avatar jgonzz (< 20) Submitted: 5/18/2007 3:11:38 PM : Outperform Start Price: $4.45 DYAX Score: +469.60

Too many promising projects inside their pipeline.

Recs

0
Member Avatar carmangar (< 20) Submitted: 4/26/2007 9:38:55 PM : Outperform Start Price: $4.48 DYAX Score: +462.42

Development of new medicine, pending outcome of further research and medical experimentation.

Recs

1
Member Avatar majakblue (< 20) Submitted: 4/14/2007 3:19:13 PM : Underperform Start Price: $6.19 DYAX Score: -289.86

Yeah, yeah, yeah, lets see if any of their candidates get past large scale phase III trials. Lets see if the patients have kidneys and liver left afterwards.

Recs

0
Member Avatar j3bajric (< 20) Submitted: 4/13/2007 2:16:00 PM : Outperform Start Price: $5.92 DYAX Score: +309.22

If it gets approved money will flow.

Recs

0
Member Avatar wbahl (94.87) Submitted: 4/13/2007 11:05:35 AM : Outperform Start Price: $6.21 DYAX Score: +287.47

This company researches cancer and is very successful.

Recs

1
Member Avatar beefsteakfarmer (58.83) Submitted: 3/13/2007 10:42:54 AM : Outperform Start Price: $3.95 DYAX Score: +534.79

The immediate future may not be encouraging but the long term will outperform the s&p. Look for the place to get in and then exit when the dx-88 sends the stock soaring for a little while.

Results 1 - 20 of 26 : 1 2 Next »

Featured Broker Partners


Advertisement